Tango Therapeutics, Inc. (TNGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 6, 2023, details the results of the 2023 Annual Meeting of Stockholders held virtually on June 6, 2023. Tango Therapeutics, Inc. is a Delaware corporation with its principal executive offices in Boston, MA. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
As of the record date (April 10, 2023), 88,209,964 shares of Common Stock were outstanding. A quorum was established with 84,622,031 shares (95.93%) present or represented by proxy. Stockholders voted on two proposals:
- Proposal 1 (Election of Directors): Malte Peters, M.D., and Mace Rothenberg, M.D., were elected as Class II directors to serve until the 2026 annual meeting.
- Proposal 2 (Ratification of Auditors): The selection of PricewaterhouseCoopers, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to report the final voting results of the Annual Meeting.
Investor Verification Checklist
- Verify the final voting tallies for the election of Malte Peters, M.D., and Mace Rothenberg, M.D.
- Confirm the ratification of PricewaterhouseCoopers, LLP as the independent auditor for fiscal year 2023.
- Review the previously filed Proxy Statement (dated April 24, 2023) for detailed background on the director nominees and auditor selection.
- Note that no financial data or operational updates were included in this specific filing.